The Galloway Lab has developed DIAL, a platform that lets researchers fine-tune the expression of synthetic genes even after they have been delivered to the target cells. The research, published in Nature Biotechnology, allows for uniform, stable control of gene expression and could be used to precisely tailor gene therapies to individual patients or cell populations.